ST. JOSEPH, Mich., June 10 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that KineMed, Inc. has licensed MetaCore for application to its ongoing multi-center Phase II prognostic study of chronic lymphocytic leukemia (CLL). KineMed’s kinetic biomarker of CLL flux as a predictor of disease course is intended to stratify indolent (simmering) versus aggressive disease.
“KineMed’s biological pathway insights and GeneGo’s database for systems biology link network complexity to physiologic phenotypes and disease genotypes which is one of the primary goals for personalized medicine. These insights will answer the challenge of determining the right medicine for the right patient at the right time,” said Gregory Hayes, Ph.D., Director of Oncology Research at KineMed. GeneGo’s genetic pathway database aligns with KineMed’s phenotypic pathway analysis and facilitates identification of genetic polymorphisms and expression patterns that directly link genetics with KineMed’s in vivo disease biomarker.
“Building cancer specific pathway analysis software and databases is a key focus area for GeneGo this year,” said Julie Bryant, VP business development. “We have a lot of expertise in this area that is reflected in our grants and publications in Science and Cancer cell.”
About KineMarker(TM) Technology
KineMed, Inc. is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to identify active drug candidates and rapidly demonstrate human proof-of-concept in selected therapeutic areas. KineMed’s KineMarker(TM) technology is designed to quickly demonstrate, preclinically and clinically, whether compounds are “on mechanism” or are acting upon specific physiologic pathways that are the basis for particular diseases. KineMed’s technology measures the kinetics of these pathways using a stable isotope labeling technique and mass isotopomer distribution analysis (MIDA), allowing observation of on-target or off-target pathologic or therapeutic changes in patients. The Company also has multiple development programs with major pharmaceutical companies, including Bayer, Merck, Organon and Roche.
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company’s web site at http://www.genego.com.
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
